Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma

Pediatric Blood and Cancer

Volumn 52, Issue 3, 2009, Pages 340-345

  Lee, Jun Ah ^a   Kim, Min Suk ^a   Kim, Dong Ho ^a   Lim, Jung Sub ^a   Park, Kyung Duk ^a   Song, Won Seok ^a   Cho, Wan Hyeong ^a   Lee, Soo Yong ^a   Jeon, Dae Geun ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Clinical factors; Osteosarcoma; Risk stratification; Survival

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMERUS; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR LOCALIZATION; DISEASE FREE SURVIVAL; FOLLOW UP; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; OSTEOSARCOMA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 58949089288     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21843     Document Type: Article

References (34)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
2. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-441.
3. Bacci G, Ferrari S, Bertoni F, et al. Histologic response of high- grade non-metastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 2001;386:186-196.
4. Lewis IJ, Weeden S, Machin D, et al. Received dose and dose- intensity of chemotherapy and outcome in non-metastatic extremity osteosarcoma. European osteosarcoma intergroup. J Clin Oncol 2000;18:4028-4037.
5. Bacci G, Ferrari S, Longhi A, et al. Relationship between dose- intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8:883-888.
6. Eselgrim M, Grunert H, Kuhne T, et al. Dose-intensity of chemotherapy for osteosarcoma and outcome in the cooperative osteosarcoma study group (COSS) trials. Pediatr Blood Cancer 2006;47:42-50.
7. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European osteosarcoma intergroup. J Natl Cancer Inst 2007;99: 112-128.
8. Schabel FM, Jr., Griswold DP, Jr., Corbett TH, et al. Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984;54:1160-1167.
9. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-1731.
10. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:93-899.
11. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11:294-305.
12. Wunder JS, Gokgoz N, Parkes R, et al. TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 2005;23:1483-1490.
13. Serra M, Picci P, Ferrari S, et al. Prognostic value of P-glycoprotein in high-grade osteosarcoma. J Clin Oncol 2007;25:4858-4860; author reply 4860-4861.
14. Fellenberg J, Dechant MJ, Ewerbeck V, et al. Identification of drug- regulated genes in osteosarcoma cells. Int J Cancer 2003;105:636-643.
15. Ifergan I, Meller I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma: Implications for the prediction of tumor chemosensitivity. Cancer 2003;98:1958-1966.
16. Kumta SM, Leung PC, Chow L, et al. Assessment of chemo- sensitivity in patients with osteogenic sarcoma using the doxor-ubicin-binding assay. J Surg Oncol 1998;68:169-172.
17. Lee SY, Jeon DG, Cho WH, et al. Preliminary study of chemosenstivity tests in osteosarcoma using a histoculture drug response assay. Anticancer Res 2006;26:2929-2932.
18. Ii S, Ueda Y, Shimazaki M, et al. Identification of novel genes involved in the synergistic antitumor effect of caffeine in osteo- sarcoma cells using cDNA microarray. Anticancer Res 2008;28: 645-653.
19. Walters DK, Steinmann P, Langsam B, et al. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res 2008;28:673-679.
20. Greene FL, Page DL, Fleming ID. et al. editors. American joint committee on cancer staging manual. 6th edition. Philadelphia: Springer; 2002.
21. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983;106:55-67.
22. Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161.
23. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030-1043.
24. Grimer RJ, Cannon SR, Taminiau AM, et al. Osteosarcoma over the age of forty. Eur J Cancer 2003;39:157-163.
25. Jeon DG, Lee SY, Cho WH, et al. Primary osteosarcoma in patients older than 40 years of age. J Korean Med Sci 2006;21:715-718.
26. Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41 -60 years: Outcome in 34 cases treated with adriamycin, cisplatinum, and ifosfamide between 1984 and 1999. Acta Orthop 2007;78:377- 384.
27. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
28. Kaste SC, Liu T, Billups CA, et al. Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity. Pediatr Blood Cancer 2004;43:723-728.
29. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134:281-297.
30. Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 2002;397:53-61.
31. Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteo- sarcoma: Comparison between preadolescent and older patients. J Pediatr Hematol Oncol 2005;27:129-134.
32. Lee JA, Kim MS, Kim DH, et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis. J Pediatr Hematol Oncol 2008;30:419-424.
33. Pieters R, Carroll WL. Biology and treatment of acute lympho-blastic leukemia. Pediatr Clin North Am 2008;55:1-20.
34. Kim MS, Song WS, Cho WH, et al. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007; 459:229-236.